

Newsletter

Volume 2, Issue 11

August 7, 2020

The LOVIT-COVID Trial

The LOVIT-COVID trial mirrors the LOVIT protocol and will include patients who are hospitalized with COVID-19 and are not taking vasopressors. This includes both patients in the hospital ward and ICU. We received approvals from Health Canada, CTO and Quebec central REB.

We are hopeful that all LOVIT sites will participate in this important sister trial. The LOVIT Coordinating Centre will be reaching out to each LOVIT Site to discuss the local feasibility.

We look forward to discussing this study with you.

COMPLETE DATA – THANK YOU!

The 3 clinical sites with the highest proportion of participants with complete data entered in the database are: 1) CIUSSS de l'Estrie-CHUS, 2) Hamilton General Hospital, and 3) Juravinski Hospital.

SECOND INTERIM ANALYSIS

The second interim analysis will be conducted when 530 participants have completed 28-day follow-up. We anticipate that this analysis will take place at the end of September 2020.

Please enter in all outstanding data and resolve all queries so that the interim analysis will not be delayed.

Please contact the Coordinating Centre with any questions.

TOP ENROLLING SITES FOR JULY 2020

- ① Sunnybrook HSC & Hamilton General Hospital: 6
- ② Juravinski Hospital: 5
- 3 CIUSSS de l'Estrie CHUS & Ottawa General: 4












516 patients have been enrolled into LOVIT, including 36 patients in July.97 patients with suspected or confirmed COVID-19 at baseline have been enrolled.




Newsletter

Volume 2, Issue 11

August 7, 2020





PLEASE CONTACT US IF YOU HAVE QUESTIONS

Marie-Hélène Masse Project leader 1-819-346-1110 ext. 14173

marie-helene.masse3@usherbrooke.ca

Julie Ménard Co-Project leader 1-819-346-1110 ext. 13534

julie.menard.ciussse-chus@ssss.gouv.qc.ca

Visit our website: http://lovit.ccctg.ca/